Yazbeck Roger, Jaenisch Simone E, Abbott Catherine A
Department of Surgery, College of Medicine and Public Health, Flinders University, GPO Box 2100, Adelaide, South Australia, 5001, Australia.
Flinders Centre for Innovation in Cancer, Flinders University, Adelaide, South Australia, Australia.
Protoplasma. 2018 Jan;255(1):375-386. doi: 10.1007/s00709-017-1129-5. Epub 2017 Jun 16.
The importance of the dipeptidyl peptidase 4 (DPP4) gene family in regulating critical biochemical pathways continues to emerge. The two most well-studied members of the family, DPP4 and fibroblast activation protein (FAP), have been investigated both as therapeutic targets for disease and as diagnostic biomarkers. The interest in DPP4 and FAP as potential disease biomarkers has been driven primarily by observations of altered expression profiles in inflammatory diseases and cancer. Furthermore, the stability and persistence of soluble DPP4 and FAP in the serum make them attractive candidate serology markers. This review summarises investigations into DPP4 and FAP as biomarkers of autoimmune disease, gut inflammation, psychosomatic disorders and malignancy and discusses their potential likelihood as clinically useful tools.
二肽基肽酶4（DPP4）基因家族在调节关键生化途径中的重要性不断显现。该家族中研究最深入的两个成员，即DPP4和成纤维细胞活化蛋白（FAP），已作为疾病治疗靶点和诊断生物标志物进行了研究。对DPP4和FAP作为潜在疾病生物标志物的关注主要源于对炎症性疾病和癌症中表达谱改变的观察。此外，可溶性DPP4和FAP在血清中的稳定性和持久性使其成为有吸引力的候选血清学标志物。本综述总结了对DPP4和FAP作为自身免疫性疾病、肠道炎症、心身疾病和恶性肿瘤生物标志物的研究，并讨论了它们作为临床有用工具的潜在可能性。
